Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL

Christopher Kim, Julia T. Molony, Victoria M. Chia, Vamsi Kota, Aaron J. Katz, Shuling Li

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mortality
Protein-Tyrosine Kinases
Drug Therapy
Therapeutics
Comorbidity
Medicare
Steroids

Keywords

  • Acute lymphoblastic leukemia
  • Medicare
  • claims
  • survival
  • treatment patterns

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. / Kim, Christopher; Molony, Julia T.; Chia, Victoria M.; Kota, Vamsi; Katz, Aaron J.; Li, Shuling.

In: Leukemia and Lymphoma, 01.01.2018.

Research output: Contribution to journalArticle

Kim, Christopher ; Molony, Julia T. ; Chia, Victoria M. ; Kota, Vamsi ; Katz, Aaron J. ; Li, Shuling. / Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. In: Leukemia and Lymphoma. 2018.
@article{9225b78d780640018478f98abe50077f,
title = "Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL",
abstract = "To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100{\%} Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5{\%}) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4{\%} received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8{\%} received both chemotherapy and TKIs, 9.8{\%} received steroids only and 2.6{\%} received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8{\%} received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7{\%}) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4{\%}). Overall, 67.5{\%} of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.",
keywords = "Acute lymphoblastic leukemia, Medicare, claims, survival, treatment patterns",
author = "Christopher Kim and Molony, {Julia T.} and Chia, {Victoria M.} and Vamsi Kota and Katz, {Aaron J.} and Shuling Li",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1538505",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL

AU - Kim, Christopher

AU - Molony, Julia T.

AU - Chia, Victoria M.

AU - Kota, Vamsi

AU - Katz, Aaron J.

AU - Li, Shuling

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

AB - To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

KW - Acute lymphoblastic leukemia

KW - Medicare

KW - claims

KW - survival

KW - treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=85058640431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058640431&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1538505

DO - 10.1080/10428194.2018.1538505

M3 - Article

C2 - 30541363

AN - SCOPUS:85058640431

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -